Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Infliximab 5 mg/kg Clear all
Withdrawn Phase 2 Interventional

Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome

NCT00514982
View directory record Official record
Conditions
Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
Interventions
Mesalamine, Infliximab, Corticosteroids, 6-Mercaptopurine, Tacrolimus, Adalimumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 26, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

Use of Infliximab for the Treatment of Pemphigus Vulgaris

NCT00283712
View directory record Official record
Conditions
Pemphigus
Interventions
Infliximab, Placebo Comparator
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Iowa City, Iowa • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Sep 26, 2026, 10:14 PM EDT
Completed Phase 1 Interventional Results available

Infliximab (Remicade) for Patients With Acute Kawasaki Disease

NCT00271570
View directory record Official record
Conditions
Kawasaki Disease
Interventions
Infliximab (Remicade), Intravenous immunoglobulin (IVIG)
Drug · Biological
Lead sponsor
University of California, San Diego
Other
Eligibility
Up to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2010 · Synced Sep 26, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

NCT02495077
View directory record Official record
Conditions
Kidney Transplant
Interventions
Infliximab, Methylprednisolone, Mycophenolate Mofetil, Tacrolimus, Thymoglobulin®, Acetaminophen, Loratadine, Placebo for Infliximab, Prednisone, Diphenhydramine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 26, 2026, 10:14 PM EDT
Terminated Phase 4 Interventional Results available

An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease

NCT02566889
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Infliximab
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
6 Years to 16 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
29
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 26, 2026, 10:14 PM EDT
Completed Phase 3 Interventional Results available

Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease

NCT02096861
View directory record Official record
Conditions
Crohn's Disease
Interventions
CT-P13, Remicade
Biological
Lead sponsor
Celltrion
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Sep 26, 2026, 10:14 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab

NCT00808210
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Infliximab, Methotrexate, Methylprednisolone, Ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
53
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Murrieta, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 26, 2026, 10:14 PM EDT
Recruiting Phase 2 Interventional

Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

NCT06136546
View directory record Official record
Conditions
Depressive Disorder, Major, Inflammation
Interventions
Infliximab, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Sep 26, 2026, 10:14 PM EDT
Completed Phase 3 Interventional Results available

Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease

NCT00760435
View directory record Official record
Conditions
Kawasaki Disease
Interventions
Infliximab, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
4 Weeks to 17 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
La Jolla, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Sep 26, 2026, 10:14 PM EDT
Completed Phase 3 Interventional Results available

Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC

NCT00094458
View directory record Official record
Conditions
Crohn Disease
Interventions
infliximab infusion; AZA placebo caps, infliximab (IFX) infusion; azathioprine (AZA) caps, infliximab (IFX) placebo infusion; azathioprine (AZA) caps
Biological · Other · Drug
Lead sponsor
Centocor Ortho Biotech Services, L.L.C.
Industry
Eligibility
21 Years to 99 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
51
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Sep 26, 2026, 10:14 PM EDT
Completed Phase 4 Interventional Results available

Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery

NCT00688636
View directory record Official record
Conditions
Crohn's Disease
Interventions
infliximab, placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 72 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2016 · Synced Sep 26, 2026, 10:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Centocor Microarray Study of Patients

NCT00462072
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn's Disease
Interventions
Infliximab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Sep 26, 2026, 10:14 PM EDT
Completed Phase 4 Interventional Results available

Dynamics of Inflammation and Its Blockade on Motivational Circuitry in Depression

NCT03006393
View directory record Official record
Conditions
Depression
Interventions
Infliximab, Placebo
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Sep 26, 2026, 10:14 PM EDT
Terminated Phase 4 Interventional Results available

Inflammation-Induced CNS Glutamate Changes in Depression

NCT03004443
View directory record Official record
Conditions
Depression
Interventions
Infliximab, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Sep 26, 2026, 10:14 PM EDT
Recruiting Phase 2Phase 3 Interventional

Precise Infliximab Exposure and Pharmacodynamic Control

NCT05660746
View directory record Official record
Conditions
Crohn Disease
Interventions
RoadMAB, Infliximab
Device · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 22 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 26, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

Protein and Energy Metabolism in Pediatric Crohn's Disease

NCT00583232
View directory record Official record
Conditions
Crohn's Disease, Protein Metabolism, Energy Metabolism
Interventions
Stable isotope infusions
Drug
Lead sponsor
Indiana University
Other
Eligibility
6 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 26, 2026, 10:14 PM EDT
Completed Phase 2 Interventional

Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation

NCT00201799
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Infliximab
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
20 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Sep 26, 2026, 10:14 PM EDT
Terminated Not applicable Interventional Results available

Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease

NCT01438151
View directory record Official record
Conditions
Crohn's Disease
Interventions
Remicade
Drug
Lead sponsor
Shradha Agarwal
Other
Eligibility
7 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Sep 26, 2026, 10:14 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease

NCT04974099
View directory record Official record
Conditions
Crohn Disease
Interventions
RoadMAB precision dashboard, Infliximab precision dosing
Device · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 22 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 26, 2026, 10:14 PM EDT
Completed No phase listed Observational

A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients

NCT00207688
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Infliximab 5 mg/kg, Infliximab 10 mg/kg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
44
States / cities
Scottsdale, Arizona • Anaheim, California • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Sep 26, 2026, 10:14 PM EDT